|
minimal PBPK in PML with IV PO dosing why is F calculated for IV?
|
|
8
|
7904
|
February 4, 2019
|
|
Materials from session about NONMEM-NLME: PD Time-to-event Analysis
|
|
0
|
13150
|
December 13, 2018
|
|
Materials from session about NONMEM-NLME: PD Categorical Response
|
|
0
|
12397
|
November 23, 2018
|
|
Q&A from session about PKPD 1comp-Emax with baseline, shape and effect
|
|
0
|
8423
|
July 13, 2018
|
|
Materials from session about NONMEM-NLME PKPD 1comp-Emax,baseline,shape and effect
|
|
0
|
13079
|
July 13, 2018
|
|
Q&A from session about NONMEM-NLME Indirect Response with IV Bolus
|
|
0
|
7760
|
July 3, 2018
|
|
Materials from session about NONMEM-NLME Indirect Response with IV Bolus
|
|
0
|
12091
|
July 3, 2018
|
|
Materials from NONMEM-NLME PD Emax inhibitory model with baseline and shape
|
|
0
|
11502
|
June 12, 2018
|
|
Materials for running NONMEM and Phoenix NLME in the cloud
|
|
0
|
12633
|
May 24, 2018
|
|
Q&A from session about nonlinear elimination model and bootstrap
|
|
0
|
7626
|
May 24, 2018
|
|
Materials from mixed absorption and model validation with VPC
|
|
0
|
12132
|
May 24, 2018
|
|
Materials from NONMEM-NLME session about nonlinear elimination model and bootstrap
|
|
0
|
12276
|
May 24, 2018
|
|
NONMEM-NLME Comparisons:TMDD Model translated from NONMEM (NM-TRAN) to Phoenix NLME (PML)
|
|
0
|
22430
|
March 22, 2018
|
|
Q&A from second session NONMEM-2-NLME: 2-compartment oral with categorical covariate
|
|
0
|
9177
|
March 13, 2018
|
|
Clearance scaling with individual body weight?
|
|
3
|
8759
|
March 12, 2018
|
|
NONMEM-NLME Comparisons: 2-compartment oral with categorical covariate
|
|
0
|
14004
|
March 8, 2018
|
|
Q&A from second session NONMEM-2-NLME: 2Comp Plasma Urine
|
|
0
|
8387
|
February 26, 2018
|
|
NONMEM-NLME Comparisons: 2-compartment IV Bolus Multiple Dose Plasma Urine
|
|
0
|
13838
|
February 23, 2018
|
|
Q&A from Intro-Session of NONMEM-NLME Comparisons
|
|
0
|
8759
|
February 10, 2018
|
|
NONMEM-NLME Comparisons 1: Intro & 1-compartment IV Bolus FOCE
|
|
0
|
12927
|
February 9, 2018
|
|
Q&A from Adaptive Trial Simulation session
|
|
0
|
9013
|
December 20, 2017
|
|
Q&A from session about TMDD QE Model
|
|
0
|
9459
|
December 18, 2017
|
|
Q&A from session about mPBPK Model
|
|
0
|
8157
|
December 15, 2017
|
|
Adaptive Simulations: Extending PML to Trial Simulations
|
|
1
|
16428
|
December 14, 2017
|
|
Target-mediated Drug Disposition (TMDD) Modeling Using the Quasi-equilibrium Assumption
|
|
1
|
15534
|
December 1, 2017
|
|
Minimal physiologically-based pharmacokinetic model for monoclonal antibodies
|
|
1
|
13659
|
November 17, 2017
|
|
Q&A from Lesson 20: Transduction Modeling
|
|
0
|
8416
|
August 11, 2017
|
|
Lesson 20: Transduction Modeling
|
|
0
|
16375
|
August 11, 2017
|
|
Q&A from Lesson 19: Dose-response-time analysis
|
|
0
|
9098
|
July 28, 2017
|
|
Lesson 19: Dose-response-time analysis
|
|
0
|
15210
|
July 28, 2017
|